Moderna to Present at the Jefferies 2022 London Healthcare Conference
Moderna (NASDAQ:MRNA) will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on November 16, 2022, at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moderna (NASDAQ:MRNA) will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on November 16, 2022, at 8:30 a.m. ET. Investors can access a live webcast through the Investors section of Moderna's website, with a replay available for 30 days post-event. Moderna has evolved significantly in a decade, boasting a diverse clinical portfolio of vaccines and therapeutics, including its COVID-19 vaccine. The company is recognized as a top biopharmaceutical employer by Science.
Details
News Market Reaction – MRNA
The recorded move for MRNA in the trading session of this news was -0.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESSWIRE / November 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, Nov. 16th at 8:30 a.m. ET.
A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View source version on accesswire.com:
https://www.accesswire.com/724548/Moderna-to-Present-at-the-Jefferies-2022-London-Healthcare-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.